ArticlePsychopharmacology2009
Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors.
Article in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 79 citations in OpenAlex.
- Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases.Physiology (Bethesda, Md.) · 2026Review
- Effects of growth hormone-releasing hormone deficiency in mice beyond growth.Reviews in endocrine & metabolic disorders · 2025Review
- Neuropeptidergic transmission shapes emergent properties of prefrontal cortical circuits underlying learning.bioRxiv : the preprint server for biology · 2025Article
- Differential serum levels of CACNA1C, circadian rhythm and stress response molecules in subjects with bipolar disorder: Associations with genetic and clinical factors.Journal of affective disorders · 2024Article
- Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting.Pharmacological reviews · 2024Review
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- Differential Serum Levels of CACNA1C, Circadian Rhythm and Stress Response Molecules in Subjects with Bipolar Disorder: Associations with Genetic and Clinical Factors.medRxiv : the preprint server for health sciences · 2024Article
- Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy.Mini reviews in medicinal chemistry · 2024Review
- Article
- Growth Hormone Action in Somatostatin Neurons Regulates Anxiety and Fear Memory.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Somatostatin signaling modulates binge drinking behavior via the central nucleus of the amygdala.Neuropharmacology · 2023Article
- Somatostatin peptide signaling dampens cortical circuits and promotes exploratory behavior.Cell reports · 2023Article
- Neuropeptide System Regulation of Prefrontal Cortex Circuitry: Implications for Neuropsychiatric Disorders.Frontiers in neural circuits · 2022Review
- Altered expression of somatostatin signaling molecules and clock genes in the hippocampus of subjects with substance use disorder.Frontiers in neuroscience · 2022Article
- Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.Molecular psychiatry · 2021Article
- Role of Basolateral Amygdalar Somatostatin 2 Receptors in a Rat Model of Chronic Anxiety.Neuroscience · 2021Article
- Molecular and functional properties of cortical astrocytes during peripherally induced neuroinflammation.Cell reports · 2021Article
- Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation.The international journal of neuropsychopharmacology · 2021Article
- Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains.International journal of molecular sciences · 2020Article
- A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders.Neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectivesSomatostatin is a cyclic polypeptide that inhibits the release of a variety of regulatory hormones (e.g., growth hormone, insulin, glucagon, and thyrotropin). Somatostatin is also widely distributed within the central nervous system (CNS), acting both as a neurotransmitter and as a neuromodulator. Recently, we showed that intracerebroventricular (i.c.v.) administration of somatostatin reduced anxiety-like and depression-like behaviors in animal models. The somatostatin receptor subtypes that are involved in these behavioral effects, however, have not been investigated. In the CNS, the neurotransmitter actions of somatostatin are mediated through five G-protein coupled receptors (sst1 to sst5). MATERIALS AND
methodsWe examined the behavioral effects of i.c.v. microinfusions of different doses of selective agonists of each of the five somatostatin receptor subtypes. Their behavioral effects were assessed in the elevated plus-maze and the forced swim apparatus, rodent models of anxiolytic and antidepressant drug effects, respectively.
resultsAnxiety-like behavior was reduced following i.c.v. infusions of a selective sst2 receptor agonist, but not after infusions of the other four receptor agonists. An antidepressant-like effect was observed following infusions of either sst2 or sst3 agonists.
conclusionsThe results add to our nascent understanding of the role of somatostatin in anxiety- and depression-like behavior and suggest a clinical role for somatostatin agonists for the simultaneous treatment of anxiety and depression, which are often comorbid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.